Transfusion-Transmitted Hepatitis

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 718-745

  Alter, Harvey J ^a   Esteban Mur, Juan I ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991497892     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch46     Document Type: Chapter

References (182)

1. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965;191:541-6.
2. London WT, Sutnick AI, Blumberg BS. Australia antigen and acute viral hepatitis. Ann Intern Med 1969;70:55-9.
3. Alter HJ, Holland PV, Purcell RH, et al. Transfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691-9.
4. Dienstag JL, Feinstone SM, Purcell RH, et al. Non-A, non-B posttransfusion hepatitis. Lancet 1977;i:560-2.
5. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 1973;182:1026-8.
6. Choo QL, Kuo G, Weiner AJ, et al. Isolation of cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
7. Alter HJ, Purcell RH, Shih JN, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A and non-B hepatitis. N Engl J Med 1989;321:1494-500.
8. Busch MP. Transfusion-transmitted viral infections: Building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 2006;46:1624-40.
9. Alter HJ. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med 2000;6:12-14.
10. Lurman A. Eine Icterusepidemie. Klin Wochenschr 1885;22:20-3.
11. Bigger JW. Jaundice in syphilitics under treatment: possible transmission of virus. Lancet 1943;i:457-8.
12. Hartfall SJ, Garland HG, Goldie W. Gold treatment of arthritis: A review of 900 cases. Lancet 1937;ii:784-8.
13. Propert SA. Hepatitis after prophylactic serum. Br Med J 1938;2:677-8.
14. Beeson PB, Chesney G, McFarlane AM. Hepatitis following injection of mumps convalescent serum. 1. Use of plasma in the mumps epidemic. Lancet 1944;i:814-15.
15. Findlay GM, MacCallum FO. Note on acute hepatitis and yellow fever immunization. Trans Soc Trop Med Hyg 1937;31:297-308.
16. Seeff LB, Beebe GB, Hoofnagle JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-70.
17. Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma: Report of seven cases. JAMA 1943;121:1332-4.
18. Morgan HW, Williamson DA. Jaundice following administration of human blood products. Br Med J 1943;1:750-3.
19. Paul JR, Havens WP, Sabin AB, et al. Transmission experiments in serum jaundice and infectious hepatitis. JAMA 1945;128:911-15.
20. Neefe JR, Gellis SS, Stokes J Jr. Homologous serum hepatitis and infectious (epidemic) hepatitis. Studies in volunteers bearing on immunologic and other characteristics of the etiologic agents. Am J Med 1946;1:3-22.
21. Krugman S, Giles JP, Hammond J. Infectious hepatitis: Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200:365-73.
22. Gocke DJ. A prospective study of posttransfusion hepatitis: The role of the Australia antigen. JAMA 1972;219:1165-70.
23. Tateda A, Kikuchi K, Numazaki Y, et al. Non-B hepatitis in Japanese recipients of blood transfusion: Laboratory screening of donor blood for hepatitis B surface antigen. J Infect Dis 1979;139:511-18.
24. Collins JD, Bassendine MF, Codd AH, et al. Prospective study of post-transfusion hepatitis after cardiac surgery in a British center. Br Med J 1983;287:1422-4.
25. Tur-Kaspa R, Shimon DV, Shalit M, et al. Posttransfusion non-A, non-B hepatitis after cardiac surgery: A prospective study. Vox Sang 1983;45:312-15.
26. Colombo M, Oldani S, Donato MF, et al. A multicenter, prospective study of posttransfusion hepatitis in Milan. Hepatology 1987;7:709-12.
27. Feinman SV, Berris B, Bojarski S. Post-infusion hepatitis in Toronto, Canada. Gastroenterology 1988;95:464-9.
28. Tremolada F, Chiapetta F, Noventa F, et al. Prospective study of posttransfusion hepatitis in cardiac surgery patients receiving only blood or also blood products. Vox Sang 1983;44:2-30.
29. Coleman PF. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 2006;12:198-203.
30. Tang H, Oishi N, Kaneko S, et al. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006;97:977-83.
31. Tang H, Delgermaa L, Huang F, et al. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005;79:5548-56.
32. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
33. Li M, Xie Y, Wu X, et al. HNF3 binds and activates the second enhancer, ENII, of hepatitis B virus. Virology 1995;214:371-8.
34. Raney AK, Johnson JL, Palmer CN, et al. Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. J Virol 1997;71:1058-71.
35. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-8.
36. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289-309.
37. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
38. Fung SK, Lok AS. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? Hepatology 2004;40:790-2.
39. Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: Results of a nationwide study. Gastroenterology 2003;125:444-51.
40. Harrison TH. Hepatitis B: Molecular virology and common mutants. Semin Liver Dis 2006;26:87-96.
41. Carman W, Thomas H, Domingo E. Viral genetic variation: Hepatitis B virus as a clinical example. Lancet 1993;341:349-53.
42. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989;170:595-7.
43. Brunetto, MR, Giarin, MM, Oliveri, F, et al. Wild-type and e antigenminus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991;88:4186-90.
44. Zarski, JP, Marcellin, P, Cohard, M, et al. Comparison of anti-HBe- positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. J Hepatol 1994;20:636-40.
45. Fattovich, G, Brollo, L, Alberti, A, et al. Long-term follow-up of anti- HBe-positive chronic active hepatitis B. Hepatology 1988;8:1651-4.
46. Shindo, M, Hamada, K, Koya, S, et al. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999;94:2237-45.
47. Hoofnagle JH, Seeff LB, Bales ZB, et al. Serologic responses in hepatitis B. In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press, 1978:219-42.
48. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
49. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;10:1104-8.
50. Yoshikawa A, Gotanda Y, Minegishi K, et al. Lengths of hepatitis B viremia and antigenemia in blood donors: Preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 2007;47:1162-71.
51. Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol 2007;46:160-70.
52. Allain JP. Occult hepatitis B virus infection: Implications in transfusion. Vox Sang 2004;86:83-91.
53. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005;42:813-19.
54. Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Lancet 1981;ii:388-93.
55. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
56. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. JAMA 1997;277:867-972.
57. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. JAMA 2000;284:229-35.
58. Zou S, Notari EP, Stramer SL, et al. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion 2004;44:1640-7.
59. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States-recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31.
60. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States-Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. MMWR 2006;55(RR-16):1-33.
61. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91:1-12.
62. Kleinman SH, Bush MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006;36(Suppl): S23-9.
63. Douglas DD, Taswell HF, Rakela J, et al. Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers. Transfusion 1993;33:212-16.
64. Wang JT, Wang TH, Sheu JC, et al. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991;163;397-9.
65. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006;36(Suppl):S33-44.
66. Kleinman SH, Kuhns MC, Todd DS, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: Implications for transfusion transmission and donor screening. Transfusion 2003;43:696-704.
67. O'Brien SF, Fearon MA, Yi QL, et al. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: The Canadian Blood Services experience. Transfusion 2007;47:1809-15.
68. Roth WK, Weber M, Petersen D, et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002;42:869-75.
69. Kleinman SH, Strong DM, Tegtmeier GG, et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005;45:1247-57.
70. Zoulim F. New nucleic acid diagnostic tests in viral hepatitis. Semin Liver Dis 2006;26:309-17.
71. Koppelman MH, Assal A, Chudy M, et al. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion 2005;45:1258-66.
72. Allain JP. International collaborative study proposal for the characterization of occult hepatitis B virus infection identified by nucleic acid or anti-HBc screening. Vox Sang 2007;92:254-7.
73. Coste J, Reesink HW, Engelfriet CP, et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: Update to 2003. Vox Sang 2005;88:289-303.
74. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
75. Visvanathan K, Lewin SR. Immunopathogenesis: Role of innate and adaptive immune responses. Semin Liver Dis 2006;26:104-15.
76. Wieland S, Thimme R, Purcell RH, et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004;101:6669-74.
77. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9.
78. Murray JM, Wieland SF, Purcell RH, et al. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A 2005;102:17780-5.
79. Thimme R, Wieland S, Steiger C, et al. CD8 ( + ) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
80. Chang JJ, Thompson AJ, Visvanathan K, et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 2007;46:1332-40.
81. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983;85:439-62.
82. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006;43(Suppl 1):S173-81.
83. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006;101(Suppl 1):S1-6.
84. McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-68.
85. Manno M, Camma C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years. Gastroenterology 2004;127:756-63.
86. Brunetto MR, Stemler M, Schodel F, et al. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989;21:151-4.
87. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;334:588-91.
88. Chu CJ, Keeffe EB, Han SH, et al. US HBV Epidemiology Study Group. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003;38:619-28.
89. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-6.
90. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58.
91. Lok AS, McMahon BJ. AASLD Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: Update of recommendations. Hepatology 2004;39:857-61.
92. Liaw YF, Leung N, Guan R, et al. Asian-Pacific Consensus Update Working Party on Chronic Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005;25:472-89.
93. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
94. Rizzetto M. The delta agent. Hepatology 1983;3:729-37.
95. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet 1982;ii:945-7.
96. Jacobson IM, Dienstag JL, Werner BG, et al. Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology 1985;5:188-91.
97. Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993;41:205-9.
98. Alter HJ, Purcell RH, Holland PV, et al. Transmissible agent in nonA, non-B hepatitis. Lancet 1978;i:459-63.
99. Tabor E, Gerety RJ, Drucker JA, et al. Transmission of non-A, non- B hepatitis from man to chimpanzee. Lancet 1978;i:463-6.
100. Shimizu YK, Feinstone SM, Purcell RH, et al. Non-A, non-B hepatitis: Ultrastructural evidence for two agents in experimentally infected chimpanzees. Science 1979;205:197-200.
101. Feinstone JM, Mihalik KB, Kamimura J, et al. Inactivation of hepatitis B virus and non-A, non-B virus by chloroform. Infect Immun 1983;4:816-21.
102. Bradley DW, McCaustland KA, Cook EH, et al. Posttransfusion non-A, non-B hepatitis in chimpanzees: Physicochemical evidence the tubule-forming agent is a small, enveloped virus. Gastroenterology 1985;88:773-9.
103. Li-Fang HE, Alling DW, Popkin TJ, et al. Non-A, non-B hepatitis virus: Determination of size by filtration. J Infect Dis 1987;156:636-40.
104. Branch AD. Hepatitis C virus RNA codes for proteins and replicates: Does it also trigger the interferon response? Semin Liver Dis 2000;20:57-68.
105. Alter HJ. To C or not to C: These are the questions. Blood 1995;85:1681-95.
106. Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The transfusion-transmitted viruses study. N Engl J Med 1981;304:989-94.
107. Stevens CE, Aach RD, Hollinger FB, et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients: An analysis of the transfusion-transmitted viruses study. Ann Intern Med 1984;101:733-8.
108. Alter HJ, Purcell RH, Holland PV, et al. The relationship of donor transaminase (ALT) to recipient hepatitis: Impact on blood transfusion services. JAMA 1981;246:630-4.
109. Koziol DE, Holland PV, Alling DW, et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 1986;104:488-95.
110. Kleinman S, Alter HJ, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by multiple-antigen HCV enzyme immunoassay. Transfusion 1992;32:805-13.
111. Blajchman MA, Bull SB, Feinman SV. Post-transfusion hepatitis: Impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group. Lancet 1995;345:21-5.
112. Kuo G, Choo OL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of non-A, non-B hepatitis. Science 1989;244:362-4.
113. Alter HJ. New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992;15:350-3.
114. Busch MP. Closing the windows on viral transmission by blood transfusion. In: Stramer SL, ed. Blood safety in the new millennium. Bethesda, MD: AABB, 2001:33-54.
115. Tanaka E, Ohue C, Aoyagi K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000;32:388-93.
116. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6.
117. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6.
118. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9.
119. Yi M, Villanueva RA, Thomas DL, et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A 2006;103:2310-15.
120. Ogata N, Alter HJ, Miller RH, et al. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 1991;88:3392-6.
121. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-44.
122. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40.
123. Bartosch B, Bukh J, Meunier JC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003;100:14199-204.
124. Meunier JC, Engle RE, Faulk K, et al. Evidence for crossgenotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 2005;102:4560-5.
125. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in-vivo. Gastroenterology 2007;132:667-78.
126. Scheel TKH, Gottwein JM, Jensen TB, et al. Development of JFH- 1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A 2008;105:997-1002.
127. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000;20:127-41.
128. Sumpter R Jr, Loo YM, Foy E, et al Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79:2689-99.
129. Ferrari C, Valli A, Galati L, et al. T-cell response to structural and non-structural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994;19:286-95.
130. Folgori A, Spada E, Pezzanera M, et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut 2006;55:1012-19.
131. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
132. Alter MJ, Gerety RJ, Smallwood LA, et al. Sporadic non-A, non-B hepatitis: Frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93.
133. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
134. Pastore G, Monno L, Santantonio T, et al. Monophasic and polyphasic pattern of alanine aminotransferase in acute non-A, non-B hepatitis: Clinical and prognostic implications. Hepatogastroenterology 1985;32:155-8.
135. Alter HJ, Hoofnagle JH. Non-A, non-B: Observations on the first decade. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. Orlando, FL: Grune & Stratton, 1984:345-54.
136. Realdi G, Alberti A, Rugge M, et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: Evidence of progression to liver cirrhosis. Gut 1982;23:270-5.
137. Omata M, Iwama S, Sumida M, et al. Clinico-pathological study of acute non-A, non-B post-transfusion hepatitis: Histological features of liver biopsies in acute phase. Liver 1981;1:201-8.
138. Iwarson S, Lindberg J, Lundin P. Progression of hepatitis non-A, non-B to chronic active hepatitis: A histologic follow-up of two cases. J Clin Pathol 1979;32:351-5.
139. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic cirrhosis. Hepatology 1998;27:914-19.
140. Kato Y, Nakata K, Omagari K, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan: Analysis of infectious hepatitis viruses. Cancer 1994;74:2234-8.
141. Seeff LB. Hepatitis in hemophilia: A brief review. In: Burk PB, Chalmers C, eds. Frontiers in liver disease. New York: Thieme- Stratton, 1981:231-41.
142. Aledort LM, Levine PH, Hilgartner M, et al. A study of liver biopsies and liver disease among hemophiliacs. Blood 1985;66:367-72.
143. Hay CRM, Preston FE, Triger DR, et al. Progressive liver disease in hemophilia: An understated problem? Lancet 1985;i:1495-7.
144. Tefler P, Sabin C, Devereux H, et al. The progression of HCC- associated liver disease in a cohort of hemophiliac patients. Br J Haemotol 1994;87:555-61.
145. Kiyosawa K, Akahane Y, Nagata A, et al. Significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sang 1982;43:45-52.
146. Kiyosawa K, Akahane Y, Nagata A, et al. Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 1984;79:777-81.
147. Okuda H, Obata H, Motoike Y, et al. Clinicopathological features of hepatocellular carcinoma: Comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology 1984;31:64-8.
148. Bruix J, Calvet X, Costa J, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma. Lancet 1989;ii:1004-6.
149. Tanaka Y, Kurbanov F, Vargas V, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006;130:703-14.
150. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
151. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis-a National Heart, Lung and Blood Institute collaborative study. Hepatology 2001;33:455-63.
152. Seeff LB, Miller RN, Rabkin CS, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
153. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic and histologic features. Ann Intern Med 1995;123:330-7.
154. Kenny-Walsh E. Irish Hepatology Research Group. Clinical outcomes after hepatitis infection from contaminated anti-globulin. N Engl J Med 1999;340:1228-33.
155. Muller R. The natural history of hepatitis C: Clinical experiences. J Hepatol 1996;24(Suppl):52-4.
156. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of donor screening. N Engl J Med 1999;341:866-70.
157. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51.
158. Reesink HW, Zeuzam S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase 1b, placebocontrolled, randomized study. Gastroenterology 2006;131:997-1002.
159. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:890-91.
160. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004;4:7-17.
161. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-84.
162. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8(10 Suppl 1):S7-13.
163. Mosley JW, Redeker AG, Feinstone SM, et al. Multiple hepatitis viruses in multiple attacks of acute viral hepatitis. N Engl J Med 1977;296:75-8.
164. Craske J, Dilling N, Stern D. An outbreak of hepatitis associated with intravenous injection of factor VIII concentrate. Lancet 1975;ii:221-3.
165. Yoshizawa H, Itoh Y, Iwakiri S, et al. Demonstration of two different types of non-A, non-B hepatitis by reinjection and cross-challenge studies in chimpanzees. Gastroenterology 1981;81:107-13.
166. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388-90.
167. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel viruslike sequences associated with human hepatitis. Nat Med 1995;6:564-9.
168. Linnen J, Wages J Jr, Zhang-Keck ZY, et al. Molecular cloning and disease association of Hepatitis G virus: A transfusion-transmissible agent. Science 1996;271:505-8.
169. Nishizawa T, Okamoto H, Konisi K, et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
170. Tanaka Y, Primi D, Wang RY, et al. Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. J Infect Dis 2001;183:359-67.
171. Leary TP, Muerhoff AS, Simons JM, et al. Sequence and genomic organization of GBV-C: A novel member of the Flaviviridae associated with human non-A-E hepatitis. J Med Virol 1996;48:60-7.
172. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated HGV infection and its relation to liver disease. N Engl J Med 1997;336:747-54.
173. Okamoto H, Nishizawa T, Kato N, et al. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol Res 1998;10:1-16.
174. Mushahwar IK, Erker JC, Muerhoff AS, et al. Molecular and biophysical characterization of TT virus: Evidence for a new virus family infecting humans. Proc Natl Acad Sci U S A 1999;96:3177-82.
175. Rodriguez-Inigo E, Casqueiro M, Bartolome J, et al. Detection of TT virus DNA liver biopsies by in situ hybridization. Am J Pathol 2000;156:1227-34.
176. Okamato H, Takahashi M, Nishizawa T, et al. Marked genomic heterogeneity and frequent mixed infection of TT virus demonstrated by PCR with primers from coding and noncoding regions. Virology 1999;259:428-36.
177. Matsumoto A, Yeo AE, Shih JW, et al. Transfusion-associated TT virus infection and its relationship to liver disease. Hepatology 1999;30:283-8.
178. Hijikata M, Takahashi K, Mishiro S. Complete circular DNA genome of a TT virus variant (isolate name SANBAN) and 44 partial ORF2 sequences implicating a great degree of diversity beyond genotypes. Virology 1999;260:17-22.
179. Umemura T, Yeo AET, Sottini A, et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001;33:1303-11.
180. Khuroo MS. Study of an epidemic of non-A, non-B hepatitis: Possibility of another human hepatitis virus distinct from posttransfusion non-A, non-B type. Am J Med 1980;68:818-824.
181. Kane MA, Bradley DW, Shrestha JM, et al. Epidemic non-A, non-B in Nepal: Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984;252:3140-5.
182. Tsarev SA, Tsareva TS, Emerson SU, et al. ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading-frame 2 protein expressed in insect cells: Identification of HEV infection on primates. J Infect Dis 1993;168:369-78.